CervoMed
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Park Plz Ste 424, Boston, Massachuset...Phone Number
(617) 744-4400Website
www.cervomed.comRevenue
<$5 MillionStock Symbol
CRVOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About CervoMed
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. Its lead therapeutic program is being investigated for multiple neurological conditions, including disorders that affect cognition, language, and motor function. Through clinical research and strategic development efforts, CervoMed aims to advance disease-modifying treatments that address significant unmet medical needs and improve outcomes for patients living with progressive brain disorders.Explore more
CervoMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CervoMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at CervoMed
Earning: See what the market has to say on CervoMed recently announced quarterly report
Funding: Get notified immidiatlly once CervoMed has new funding data
Product Launch: Get notified when CervoMed launches new products
Click to see if CervoMed had a recent Job posting/layoffs
CervoMed, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CervoMed is spiking on competitors!
Check if CervoMed has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to CervoMed
Compare insights from companies similar to CervoMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CervoMed financials insights
Gather financial insights about CervoMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$149.4M
2026
Stock/Share Issuance
$10.5M
CervoMed Tech Stack
A closer look at the technologies used by CervoMed
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
CervoMed News & Media
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or aboutCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer’s disTrust tied to CervoMed director buys 955K units | CRVO Insider Trading - Stock Titan
Trusts linked to director Joshua Boger bought 955,414 CervoMed units at $3.14, each with one share plus Series B and C warrants featuring a 19.99% cap.CervoMed Insiders Lose Out As Stock Sinks To US$2.45
Insiders who bought US$455.1k worth of CervoMed Inc.'s ( NASDAQ:CRVO ) stock at an average buy price of US$7.98 over...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CervoMed
Sign Up For FreeTo access detailed company insights
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. I... Read More
